PT2821416T - Anticorpo de recetor il-23 anti- humano inovador - Google Patents

Anticorpo de recetor il-23 anti- humano inovador

Info

Publication number
PT2821416T
PT2821416T PT13754932T PT13754932T PT2821416T PT 2821416 T PT2821416 T PT 2821416T PT 13754932 T PT13754932 T PT 13754932T PT 13754932 T PT13754932 T PT 13754932T PT 2821416 T PT2821416 T PT 2821416T
Authority
PT
Portugal
Prior art keywords
human
receptor antibody
novel anti
novel
antibody
Prior art date
Application number
PT13754932T
Other languages
English (en)
Inventor
Yonezawa Atsuo
Ohori Makoto
Sasaki Takanori
Sato Hiromu
Taguchi Katsunari
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of PT2821416T publication Critical patent/PT2821416T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT13754932T 2012-02-28 2013-02-27 Anticorpo de recetor il-23 anti- humano inovador PT2821416T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012040958 2012-02-28

Publications (1)

Publication Number Publication Date
PT2821416T true PT2821416T (pt) 2018-12-14

Family

ID=49082649

Family Applications (1)

Application Number Title Priority Date Filing Date
PT13754932T PT2821416T (pt) 2012-02-28 2013-02-27 Anticorpo de recetor il-23 anti- humano inovador

Country Status (7)

Country Link
US (1) US9371391B2 (pt)
EP (1) EP2821416B1 (pt)
JP (1) JP6137169B2 (pt)
ES (1) ES2701064T3 (pt)
PL (1) PL2821416T3 (pt)
PT (1) PT2821416T (pt)
WO (1) WO2013129454A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018204489A1 (en) * 2017-05-02 2018-11-08 Dana-Farber Cancer Institute, Inc. Il-23r antagonists to reprogram intratumoral t regulatory cells into effector cells
EP4416177A2 (en) 2021-10-11 2024-08-21 Y-Trap, Inc. Compositions and methods that inhibit il-23 signaling
CN113698484B (zh) * 2021-10-13 2023-07-18 浙江博锐生物制药有限公司 抗il-23r抗体及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP0690132B1 (en) 1993-03-11 2003-12-17 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Anti-hiv monoclonal antibody
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP2395025A1 (en) 2007-02-28 2011-12-14 Schering Corporation Engineered Anti-IL-23R Antibodies
WO2010027767A1 (en) 2008-08-27 2010-03-11 Schering Corporation Engineered anti-il-23r antibodies
CA2741566A1 (en) 2008-11-03 2010-06-03 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
TW201249867A (en) * 2011-04-01 2012-12-16 Astellas Pharma Inc Novel anti-human il-23 receptor antibody

Also Published As

Publication number Publication date
EP2821416B1 (en) 2018-10-03
PL2821416T3 (pl) 2019-01-31
US20150126713A1 (en) 2015-05-07
EP2821416A1 (en) 2015-01-07
US9371391B2 (en) 2016-06-21
WO2013129454A1 (ja) 2013-09-06
JPWO2013129454A1 (ja) 2015-07-30
EP2821416A4 (en) 2015-06-17
ES2701064T3 (es) 2019-02-20
JP6137169B2 (ja) 2017-05-31

Similar Documents

Publication Publication Date Title
HK1215267A1 (zh) 嵌合抗原受體
HK1213922A1 (zh) 嵌合抗原受體
EP2866833A4 (en) CRYSTALLINE ANTIBODIES AGAINST HUMAN IL-23
HK1210620A1 (en) Multi-specific monoclonal antibodies
ZA201400768B (en) Interleukin-31 monoclonal antibody
EP2765193A4 (en) CHIMERIC ANTIGEN RECEPTOR
EP2930240A4 (en) ANTI-FOLR1 ANTIBODY
EP2832855A4 (en) NEW ANTI-SIGLEC ANTIBODY-15
EP2844290A4 (en) NOVEL ANTIBODIES
ZA201407316B (en) Anti-fgfr2 antibody
HK1223123A1 (zh) 新穎抗人類 受體抗體
EP2826790A4 (en) GREMLIN-1 ANTIBODY
ZA201407079B (en) Cdr-modified anti-siglec-15 antibody
PT2695897T (pt) Novo anticorpo anti-receptor de il-23 humano
EP2804876A4 (en) NEW ANTIBODIES
GB201220242D0 (en) Antibody
EP2796550A4 (en) NEW ANTIBODY ANTI CTGF HUMAN
EP2821416A4 (en) NOVEL ANTIBODIES TO THE HUMAN IL-23 RECEPTOR
EP2848633A4 (en) ANTI-CXADR ANTIBODY
EP2811018A4 (en) ANTI-BODY ANTI-sAPPß